INDISCRIMINATE USE OF GLP-1 ANALOGUES, SUCH AS SEMAGLUTIDE (OZEMPIC®), FOR AESTHETIC PURPOSES AND MULTIDISCIPLINARY ACTION IN CARE AND RISK PREVENTION. (2025). Editora Impacto Científico, 342-356. https://periodicos.newsciencepubl.com/editoraimpacto/article/view/9073